Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents
Authors:
- 23 August 2017
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 63 (1) , 209-217
Abstract
Background As an important quality measure, the rates of recommended immunizations among immunocompromised inflammatory bowel disease (IBD) patients in community practice have not been well studied. Aims This study sought to investigate the rates and predictors of recommended immunizations and screening tests among IBD patients receiving anti-tumor necrosis factor (TNF) therapy in a large integrated healthcare organization. Methods We conducted a retrospective cohort study of 1401 IBD patients on anti-TNF therapy between 2010 and 2013 within the Kaiser Permanente Northern California healthcare system. The rates of vaccinations and screening tests were quantified, and the associated predictors were investigated. Results Vaccination rates for influenza and pneumococcus were 43.5 and 24.1%, respectively. The majority of patients (73.7%) received hepatitis B screening and/or vaccine. Patients receiving infliximab had higher rates of pneumococcal vaccine (P = 0.002), hepatitis B screening (P < 0.001), and tuberculin skin test (P < 0.001) compared with patients receiving adalimumab. Older patient age (≥50 years) was associated with higher likelihood of having HBsAg test (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.2–2.0, P = 0.002), influenza vaccine (OR 2.6 [2.1–3.4], P < 0.001), and pneumococcal vaccine (OR 4.0 [3.0–5.3], P < 0.001). In contrast, older providers (≥50 years) were associated with significantly lower likelihood of their patients’ having hepatitis A and B screening tests, and pneumococcal vaccination. Conclusions The rates of immunizations for IBD patients receiving anti-TNF treatment were lower than recommended. Structured reminders for vaccinations and education for both patients and providers (older physicians in particular) may prove beneficial in improving immunization rates among immunocompromised IBD patients.Keywords
Funding Information
- Kaiser Permanente (Kaiser Permanente Northern California Graduate Medical Education Research, supported by Kaiser Permanente Community Benefits Grant)
This publication has 22 references indexed in Scilit:
- Opportunistic Infections Due to Inflammatory Bowel Disease TherapyInflammatory Bowel Diseases, 2014
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised HostClinical Infectious Diseases, 2013
- A Quality Improvement Project Significantly Increased the Vaccination Rate for Immunosuppressed Patients with IBDInflammatory Bowel Diseases, 2013
- A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel diseaseJournal of Gastroenterology, 2012
- Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patientsInflammatory Bowel Diseases, 2012
- Vaccinating the inflammatory bowel disease patient: Deficiencies in gastroenterologists knowledgeInflammatory Bowel Diseases, 2011
- Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologistsInternal Medicine Journal, 2011
- Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel DiseaseGastroenterology, 2008
- Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosisGut, 2008
- Infecciones oportunistas en pacientes con enfermedad inflamatoria intestinal bajo tratamiento inmunosupresorGastroenterología y Hepatología, 2003